

May 21, 2015

Announcement of the receipt of a notification of the achievement of a milestone associated with the progress of a Phase III clinical trial of the cancer-specific peptide vaccine S-588410

OncoTherapy Science, Inc. (President & CEO: Masaharu Mori; hereinafter, "OncoTherapy") announces that Shionogi & Co., Ltd. (Head office: Chuo-ku, Osaka, President and CEO: Isao Teshirogi, hereinafter "Shionogi") has enrolled the first patient in the Phase III clinical trial of the cancer-specific peptide vaccine S-588410, which OncoTherapy has out-licensed to Shionogi, for esophageal cancer. OncoTherapy received notification of the achievement of a milestone from Shionogi in connection with the progress of the clinical trial, under the Agreement between both parties announced on February 23, 2015.